KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Petmed Express (PETS) EBITDA (2016 - 2025)

Petmed Express' EBITDA history spans 16 years, with the latest figure at -$10.5 million for Q4 2025.

  • For Q4 2025, EBITDA fell 2226.44% year-over-year to -$10.5 million; the TTM value through Dec 2025 reached -$59.0 million, down 10032.83%, while the annual FY2025 figure was $3.6 million, 216.59% up from the prior year.
  • EBITDA reached -$10.5 million in Q4 2025 per PETS's latest filing, down from -$8.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $9.0 million in Q1 2021 to a low of -$34.1 million in Q2 2025.
  • Average EBITDA over 5 years is -$529450.0, with a median of $645000.0 recorded in 2023.
  • Peak YoY movement for EBITDA: soared 1074.67% in 2024, then tumbled 2226.44% in 2025.
  • A 5-year view of EBITDA shows it stood at $5.9 million in 2021, then plummeted by 97.06% to $172000.0 in 2022, then plummeted by 858.14% to -$1.3 million in 2023, then surged by 65.49% to -$450000.0 in 2024, then crashed by 2226.44% to -$10.5 million in 2025.
  • Per Business Quant, the three most recent readings for PETS's EBITDA are -$10.5 million (Q4 2025), -$8.4 million (Q3 2025), and -$34.1 million (Q2 2025).